Welcome to our dedicated page for Prophase Labs SEC filings (Ticker: PRPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProPhase Labs, Inc. (PRPH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. ProPhase is a biotech, genomics, and consumer health company, and its filings offer detailed information on diagnostics programs, genomics initiatives, consumer products, financing arrangements, and governance matters.
Investors can review current and periodic reports such as Forms 10-K and 10-Q (when available) for discussions of business operations, risk factors, and financial statements. Form 8-K filings are particularly active for PRPH and capture material events including the 1-for-10 reverse stock split approved and implemented in late 2025, at-the-market equity sales agreements, senior secured convertible notes and warrants described in the S-1 registration statement, and updates on legal matters and lease forbearance arrangements. Our AI tools highlight the key points in these filings, such as the rationale for the reverse split, the structure of financing instruments, and the implications of special meeting votes.
For those analyzing capital structure and dilution, the S-1 registration statement filed in October 2025 details the terms of senior secured convertible notes, associated warrants, and registration rights for resale of common stock. AI summaries can help clarify conversion mechanics, floor price concepts, warrant terms, and potential issuance scenarios, without requiring readers to parse every technical clause.
This page also surfaces proxy materials like the definitive proxy statement for the November 2025 special meeting, where stockholders voted on digital asset charter amendments, digital treasury shares, tokenized issuance authority, and stock split and share authorization proposals. Our AI analysis can outline what each proposal authorizes and how it may affect governance, treasury strategy, and future capital actions.
As new filings are posted to EDGAR, they are updated here in near real time. Users can quickly locate 8-Ks on financial results, legal proceedings, or strategic LOIs, as well as registration statements and other key documents. The combination of official SEC text and AI-generated explanations helps investors, analysts, and researchers understand how ProPhase’s diagnostics, genomics, consumer health businesses, and financing activities are reflected in its regulatory record.
ProPhase Labs (PRPH) entered into an At‑the‑Market (ATM) Sales Agreement with WestPark Capital, allowing the company to offer and sell shares of its common stock from time to time through WestPark as sales agent. Sales, if any, will be made under ProPhase’s effective Form S‑3 (File No. 333-283182), declared effective on November 20, 2024, including through the Nasdaq Capital Market, as “at the market offerings” under Rule 415. The agent will receive 3.0% of gross proceeds from any share sales and reimbursement of certain expenses.
The agreement includes customary representations, warranties, indemnification and contribution provisions. ProPhase is not obligated to sell shares, may suspend sales, and either party may terminate the agreement upon notice.
ProPhase Labs (PRPH) launched an at-the-market (ATM) offering of up to $4,265,221 of common stock through WestPark Capital under a Sales Agreement. WestPark will act as sales agent or principal with a 3.0% commission, and sales may occur from time to time on Nasdaq. The company may also issue, sell, or pledge shares as collateral for loan or credit facilities, which will count toward the same aggregate cap.
The company affirms “baby shelf” eligibility: public float was $23,330,689 based on 38,884,482 non‑affiliate shares at $0.60 (October 6, 2025), and it has sold $3,277,563 of securities in the prior 12 months, allowing up to $4,265,221 under General Instruction I.B.6. Use of proceeds includes working capital, product development and commercialization, acquisitions, debt repayment, and potential exploration of a crypto treasury strategy; up to 25% of ATM net cash proceeds may be applied to July 2025 private placement Notes if required by the lead investor.
Shares outstanding were 41,541,205 as of October 6, 2025. The prospectus illustrates up to 48,987,772 shares after the offering, assuming 7,108,701 shares sold at $0.60 per share; actual issuance will vary with sale prices and any collateral arrangements.
ProPhase Labs, Inc. entered into a Strategic Advisory and Private Placement Agreement with ThinkEquity LLC for a proposed best-efforts private placement of approximately
As compensation, ProPhase agreed to pay an 8% cash placement agent fee on the aggregate purchase price of securities sold, payable from gross proceeds at closing. The company will also issue placement agent warrants equal to 8% of the shares placed, including shares underlying any convertible securities, plus additional advisory warrants: 1,250,000 warrants at closing, 1,250,000 warrants when the company accumulates
ProPhase Labs reported that stockholders approved several key measures at a special meeting. The company amended its certificate of incorporation to increase authorized common shares from 50,000,000 to 1,000,000,000, enabling a larger share reserve for a July 2025 convertible note and warrant financing that requires reserving 400% of the maximum shares issuable.
Stockholders also approved updated equity incentive plans for employees and directors, an advisory share repurchase program, and authorization under Nasdaq rules for issuances in a private placement. A prior $500,000 loan from Chairman and CEO Ted Karkus now carries a fully exercisable warrant for 500,000 common shares after the share increase was approved. As of August 1, 2025, 41,541,205 common shares were outstanding and entitled to vote, with 63.54% of shares represented at the meeting.
ProPhase Labs director and CEO & Chairman Ted Karkus was issued a warrant to purchase 500,000 shares of ProPhase Labs common stock as of 09/09/2025. The warrant has a $0.60 exercise price, a five-year term expiring 09/09/2030, and was issued as consideration tied to a related-party loan dated 06/22/2025. Issuance occurred only after shareholders approved increasing authorized common shares from 50,000,000 to 1,000,000,000 on 09/09/2025. The transaction is reported on Form 4 and the warrant details are described in the company’s Current Report on Form 8-K/A filed 06/26/2025.
ProPhase Labs, Inc. terminated its Common Stock Purchase Agreement with Keystone Capital Partners, LLC, effective August 28, 2025. This agreement had provided an equity line facility giving ProPhase the right, but not the obligation, to sell common stock to Keystone for up to approximately $7.7 million in aggregate purchase price.
The company exercised its contractual right to end the facility in its sole discretion with one trading day’s written notice and incurred no penalties or termination fees. The company states there are no other material relationships between ProPhase or its affiliates and Keystone beyond this terminated agreement.
ProPhase Labs, Inc. filed a Form 8-K to update shareholders on its proxy process and special meeting timing. The company issued a press release on August 19, 2025 stating it has filed its Definitive Proxy Statement with the SEC and received a “no further comments” letter from the SEC’s Division of Corporation Finance, Office of Life Sciences, confirming completion of the review of its Preliminary Proxy Statement on Schedule 14A.
The company also adjourned its Special Meeting of Shareholders from August 29, 2025 to September 9, 2025 at 4:00 p.m. Eastern Time in Lynbrook, New York. The additional time is intended to allow for proper dissemination of definitive proxy materials and to maintain compliance with applicable regulations. The filing reiterates standard forward-looking statement cautions, including references to the company’s ability to regain or maintain compliance with Nasdaq listing standards.
ProPhase Labs (PRPH) filed a Definitive Proxy Statement presenting proposals for shareholders including amended equity plans and governance changes. The company proposes an Amended and Restated 2025 Employee Equity Compensation Plan and an Amended and Restated 2025 Directors' Equity Compensation Plan that, if approved, will add share reserves of +3,000,000 and +500,000 shares respectively and will supersede the 2022 plans. Individual option awards shown include grants such as 100,000, 300,000 (strike 6.00 expiring 3/16/2031), and other grants to executives and directors.
The proxy also lists director nominees and board information, including named directors Ted Karkus, Louis Gleckel, Warren Hirsch and others, and notes plan terms of 10 years for awarded options. Several proposals include charter/bylaw amendments and a Certificate of Amendment.
ProPhase Labs, Inc. reported net revenues of $1.25 million for the three months ended June 30, 2025, down from $1.50 million a year earlier, and $2.68 million for the six months versus $3.86 million a year prior. Gross profit improved to $0.73 million for the quarter from a loss the prior year, reflecting lower cost of goods sold.
The company had $169 thousand in cash and $42.04 million in total assets at June 30, 2025, versus $678 thousand and $63.20 million at year-end 2024. Loss from continuing operations after income taxes was $4.47 million for the quarter and $9.15 million for the six months. The six-month results include an $8.75 million gain on disposal of discontinued operations (PMI). Stockholders' equity was $11.44 million and shares outstanding were 41,541,205 as of August 11, 2025.
Material developments disclosed include the sale of PMI, completion of a BE-Smart validation study with >95% technical success, termination and settlement of New York leases with related asset write-offs and a $1.4 million lease termination loss, equity financing through a Keystone ELOC raising approximately $3.6 million net, and new short-term loan financings including two $625,000 notes issued June 22, 2025 with attached warrants.
ProPhase Labs (PRPH) furnished a press release announcing its financial results for the second quarter ended June 30, 2025 and scheduled a conference call on August 13, 2025 at 2:00 p.m. Eastern Time to discuss those results and corporate developments. The filing explicitly states the press release and related information are being furnished and shall not be deemed "filed" under the Exchange Act or incorporated by reference, and it attaches the press release as Exhibit 99.1 plus a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104. The report also contains forward-looking language addressing the company’s ability to regain Nasdaq listing compliance or obtain additional time from Nasdaq.